What is HC Wainwright’s Estimate for RYTM FY2027 Earnings?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Stock analysts at HC Wainwright issued their FY2027 earnings per share estimates for Rhythm Pharmaceuticals in a research report issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of $1.06 for the year. HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.06. The company had revenue of $57.25 million during the quarter, compared to the consensus estimate of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The firm’s revenue for the quarter was up 36.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.72) EPS.

RYTM has been the subject of a number of other reports. Morgan Stanley reissued an “overweight” rating and issued a $150.00 target price on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Citigroup reiterated an “outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Friday, December 12th. Canaccord Genuity Group cut their price objective on Rhythm Pharmaceuticals from $141.00 to $140.00 and set a “buy” rating for the company in a report on Monday. Stifel Nicolaus set a $131.00 target price on shares of Rhythm Pharmaceuticals in a report on Thursday, February 26th. Finally, Wells Fargo & Company dropped their target price on shares of Rhythm Pharmaceuticals from $145.00 to $136.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.07.

Rhythm Pharmaceuticals Stock Down 5.7%

NASDAQ:RYTM opened at $89.56 on Tuesday. The firm has a market capitalization of $6.12 billion, a PE ratio of -28.80 and a beta of 2.06. Rhythm Pharmaceuticals has a 12-month low of $45.90 and a 12-month high of $122.20. The firm has a 50-day moving average price of $103.08 and a 200 day moving average price of $103.51.

Insiders Place Their Bets

In related news, CFO Hunter C. Smith sold 4,385 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the transaction, the insider owned 20,814 shares of the company’s stock, valued at $2,310,354. This trade represents a 13.86% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 25,003 shares of company stock valued at $2,589,015. 6.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its stake in Rhythm Pharmaceuticals by 303.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after purchasing an additional 141 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after buying an additional 322 shares during the period. Optiver Holding B.V. grew its holdings in shares of Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after buying an additional 144 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its position in Rhythm Pharmaceuticals by 73.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after buying an additional 145 shares during the last quarter.

Trending Headlines about Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Price target raised to $176, a sizable bullish revision that supports upside for RYTM. Price Target Raised to $176
• Positive Sentiment: Price target raised to $143 by another analyst — another explicit vote of confidence that could buoy sentiment. Price Target Raised to $143
• Positive Sentiment: HC Wainwright published a bullish FY‑2027 EPS forecast of $1.06 and reiterates a “Buy” rating with a $110 target — the EPS call is particularly notable because it contrasts sharply with the street consensus, implying a materially improved outlook if realized. MarketBeat RYTM Coverage
• Neutral Sentiment: Canaccord set a $140 price target (a small trim from $141) and maintains a buy stance — modestly positive but largely neutral given the tiny cut. Canaccord $140 Target
• Neutral Sentiment: Yahoo Finance published a valuation review of RYTM after the recent pullback — useful context for investors assessing whether current weakness creates a buying opportunity or signals overvaluation. Valuation Article
• Negative Sentiment: HC Wainwright lowered its price target from $125 to $110 in a separate note — a downward revision that may be cited by sellers despite the firm’s continued Buy rating and optimistic EPS estimate. HC Wainwright Price Target Cut to $110

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.